LEADER 01283nam 2200361Ia 450 001 996384287803316 005 20221108002752.0 035 $a(CKB)1000000000593006 035 $a(EEBO)2240892162 035 $a(OCoLC)18111236 035 $a(EXLCZ)991000000000593006 100 $a19880620d1670 uy | 101 0 $aeng 135 $aurbn||||a|bb| 200 12$aA collection of private devotions, fitted for every day of the week$b[electronic resource] /$fby Thomas Wooley 210 $aLondon $cPrinted for Hen. Twyford and Timothy Twyford ...$d1670 215 $a[17], 150 p 300 $aAdded engraved t.p.: A collection of private devotion / composed by Thomas Woolley for ye use of his childr̃. 300 $aRunning title: Private devotions. 300 $aReproduction of original in the Huntington Library. 330 $aeebo-0113 606 $aChildren$vPrayer-books and devotions$xEnglish 606 $aDevotional literature 615 0$aChildren$xEnglish. 615 0$aDevotional literature. 700 $aWooley$b Thomas$01017613 801 0$bEAH 801 1$bEAH 801 2$bWaOLN 906 $aBOOK 912 $a996384287803316 996 $aA collection of private devotions, fitted for every day of the week$92388243 997 $aUNISA LEADER 04890nam 22005655 450 001 9910619287203321 005 20260116155527.0 010 $a981-19-3995-0 024 7 $a10.1007/978-981-19-3995-2 035 $a(MiAaPQ)EBC7120445 035 $a(Au-PeEL)EBL7120445 035 $a(CKB)25181491800041 035 $a(PPN)265859085 035 $a(DE-He213)978-981-19-3995-2 035 $a(OCoLC)1348932388 035 $a(EXLCZ)9925181491800041 100 $a20221020d2022 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPulmonary Tuberculosis and Its Prevention /$fedited by Takefumi Saito, Masahiro Narita, Charles L. Daley 205 $a1st ed. 2022. 210 1$aSingapore :$cSpringer Nature Singapore :$cImprint: Springer,$d2022. 215 $a1 online resource (292 pages) 225 1 $aRespiratory Disease Series: Diagnostic Tools and Disease Managements,$x2509-5560 311 08$aPrint version: Saito, Takefumi Pulmonary Tuberculosis and Its Prevention Singapore : Springer,c2022 9789811939945 320 $aIncludes bibliographical references. 327 $aPart I. Epidemiology and Pathogenesis -- Chapter 1. Epidemiology -- Chapter 2. Immunology -- Chapter 3. Impact of Biologic and JAK Inhibitor Therapies on TB: How do Biologic Therapies Affect the Presentation and Treatment Course of Pulmonary TB? -- Chapter 4. Advances in Mycobacterial Laboratories: What is the latest laboratory approach to diagnose and manage pulmonary tuberculosis? -- Part II Pulmonary Tuberculosis -- Chapter 5. Advances in Diagnostics of Pulmonary tuberculosis: What is the Latest Approach to Diagnose Pulmonary TB? -- Chapter 6. HRCT diagnosis of pulmonary tuberculosis: Microlesions -- Chapter 7. Advances in Treatment of Drug Resistant Pulmonary TB: What is the latest approach to treat drug-resistant pulmonary TB? -- Chapter 8. The Role of Surgical Interventions for Pulmonary TB: What is the Role of Surgical Intervention in Pulmonary TB? -- Part III Latent TB Infection: TB Prevention -- Chapter 9. Advances in Diagnosis of Latent TB Infection: What is the Latest Approach to Diagnose Latent TB Infection to Prevent TB? -- Chapter 10. Advances in Treatment of Latent TB Infection: What is the Latest Approach to Treat Latent TB Infection to Prevent Pulmonary TB? -- Part IV Research Areas -- Chapter 11. TB vaccines: What Type of TB Vaccines are Studied and will be Available in the Future? -- Chapter 12. Clinical Trials of Pulmonary TB: Challenges and Opportunities -- Chapter 13. Contributions of Japanese Scholars to Advances in Clinical Tuberculosis Management: In TB World, What Kind of Achievements are Accomplished by Japanese Researchers?. 330 $aEvery year, 10 million people fall ill with tuberculosis (TB) in the world, and of those, 1.5 million people die even though it is a preventable and curable disease. As a result, TB remains the world?s leading infectious cause of death. On the other hand, in industrialized countries, the TB incidence has fallen to a historic low, and clinicians? experience with TB diminished significantly in recent years. Additional challenges for clinicians include atypical presentation of TB in the immunocompromised, especially among the elderly, and an increasing number of patients with drug-resistant TB. Delayed diagnosis of TB leads to the spread of TB including nosocomial transmission because TB is an air-borne infectious disease, and suboptimal treatment can result in development of drug resistance. Furthermore, treatment of latent TB infection (LTBI) can prevent future TB cases but it has been under-utilized despite recent innovations in diagnosis and treatment regimens of LTBI. This bookfocuses on advances in diagnostic tools and treatment for both TB disease and latent TB infection. Each chapter/topic is written by one of the top TB experts in the field and the authors are from Japan and the US. Pulmonary Tuberculosis and its Prevention offers up-to-date information that can be incorporated into a busy practice of clinicians while they can appreciate broad international perspectives and gain in-depth knowledge on TB. 410 0$aRespiratory Disease Series: Diagnostic Tools and Disease Managements,$x2509-5560 606 $aInternal medicine 606 $aInternal Medicine 606 $aTuberculosi$2thub 608 $aLlibres electrònics$2thub 615 0$aInternal medicine. 615 14$aInternal Medicine. 615 7$aTuberculosi 676 $a614.542 702 $aSaito$b Takefumi 702 $aNarita$b Masahiro 702 $aDaley$b Charles L. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910619287203321 996 $aPulmonary Tuberculosis and Its Prevention$92954790 997 $aUNINA